Hypodermic needles are a typical category characterized by low unit price, high volume, and strong regulatory requirements. Global annual demand is conservatively estimated at over 160 billion units (including derivatives such as insulin pen needles, vaccine needles, and blood collection needles), with China supplying approximately 55%–60%. However, pricing remains under pressure from BD, Terumo, and Nipro.

The industrial agglomeration effect is evident.

Two Major Domestic Syringe Manufacturing Clusters

• Yangzhou (Guangling), Jiangsu - Primarily focused on wire drawing and finished product assembly, with headquarters of Kangdelai and Volt located here. The region is fully equipped with wire-drawing dies, silicone coating facilities, and can source the entire BOM within a 50-kilometer radius.
• Shandong/Tianjin - Driven by the Weigao group, specializing in integrated IV and needle products, with strong hospital distribution channels.
• The advantage of this cluster is "modify the mold and get samples in three days," but the downside is severe homogenization-there are reportedly over 200 syringe manufacturers around Yangzhou, most competing on the price of 25G vaccine needles by cutting five jiao per thousand units.

Three Hurdles in Going Global

• MDR transition costs: After the implementation of the EU's MDR in 2021, many small and medium-sized Chinese needle manufacturers abandoned CE certification, thereby creating market space for leading players. However, this also means higher compliance costs for companies doing business in Europe.
• U.S. anti-dumping risks: There is already a precedent of Section 337 investigations in the U.S. targeting combined syringe-and-needle products. While pure needle tubes are currently safe, exporting complete sets including needles, hubs, and protective caps requires caution regarding origin determination.
• Raw material volatility: The wire grade used for needle tubes-medical-grade precision wire rod-is supplied domestically by Baosteel and Yongxing Materials. However, high-end 316L wire rod still relies partially on Japanese Nippon Steel and Swedish Sandvik. Exchange rates and tariffs will consequently affect the FOB price of needle tubes.

Two Future Growth Areas

India/Southeast Asia localization: The Indian government's "Make in India" initiative has imposed tariffs on imported syringes, but domestic production capacity is insufficient. Chinese manufacturers' previous model of joint ventures combined with technology transfer offers greater stability than pure exports.

Home-based chronic disease applications: Insulin pen needles and GLP-1 self-injection needles (driven by the surge in semaglutide) are ultra-fine 32G–33G needles, priced 3–5 times higher than standard needles and featuring high viscosity-this niche segment is where Chinese manufacturers should focus their efforts over the next five years.

For domestic manufacturers: Continuing to compete on price with 25G vaccine needles is a dead end. The next opportunity lies in upgrading to 32G+ ultra-fine siliconized pen needles, expanding into Southeast Asian joint ventures, and deepening into dual MDR and FDA certification.